Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CVX-060 + sunitinib
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
CVX-060 + sunitinib is a combination therapy investigated for the treatment of advanced solid tumors, including renal cell carcinoma. CVX-060 is a humanized monoclonal antibody fused to two Angiopoietin-2 (Ang2) binding peptides, acting as an Ang2 inhibitor. Sunitinib is an orally administered small-molecule multi-targeted receptor tyrosine kinase inhibitor that blocks several RTKs involved in tumor growth and angiogenesis, including VEGF receptors (VEGFR1–3), PDGF receptors, KIT (CD117), RET, CSF1R, and FLT3. The combination was studied to assess safety and efficacy in patients with advanced cancers; however, clinical trials did not show improved antitumor efficacy over single-agent sunitinib[2][5][7]. Sunitinib is approved for use in gastrointestinal stromal tumor (GIST), advanced renal cell carcinoma (RCC), adjuvant RCC following nephrectomy at high risk of recurrence, and progressive pancreatic neuroendocrine tumors[4][6][8].
- Brand names
- Sutent
02
Targets
ANGPT2 (Angiopoietin-2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)CSF1R (Macrophage colony-stimulating factor receptor)PDGFRB (Platelet-derived growth factor receptor beta)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on CVX-060 + sunitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CVX-060 + sunitinib.